GRAND ROUNDS
AT SILVER HILL HOSPITAL

TUESDAY, FEBRUARY 2, 2010
12:30pm – 1:30pm

EMERGING CLINICAL APPLICATIONS OF GENOTYPE-GUIDED PSYCHOTROPICS FOR DEPRESSIVE DISORDERS

Presented by
Gualberto Ruano, M.D.
Director of Genetics Research at Hartford Hospital and President of Genomas
The effectiveness of drugs and their potential for both benefit and side effects are not only the result of drug selection and dose but also the rate of drug metabolism and target interaction. For many drugs, this metabolism is accomplished by the Cytochrome P450 enzyme system located in the liver and small intestine. Variability in the CYP system, accumulated in humans since prehistoric times, results in strikingly different drug levels, drug effectiveness and drug safety among individuals when the recommended dose is designed to treat the “average” person. These variances, particularly relevant to drugs used in mental health and pain control, can now be measured by DNA typing before treatment. Drug doses can then be tailored to provide safe and effective therapy for individual patients (DNA-Guided Medicine).

At the end of the program, participants will be able to:
1) Discuss the clinical utility of cytochrome P450 (CYP450) genotyping in management of psychiatric drugs.
2) Describe the case presentations and patient profiles where use of CYP450 genotyping can diagnose clinically intensive side effects.
4) Appraise the features of next-generation multi-genotype arrays to diagnose and prevent the cardiometabolic and neuroendocrine side effects of antipsychotic drugs.

Silver Hill Hospital is accredited by the Connecticut State Medical Society to sponsor continuing medical education for physicians. Silver Hill Hospital designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Space is limited. To register for this program, call (203) 801-2378.